Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern

benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern

Zinger Key Points
- CagriSema led to a 20.4% weight loss at 68 weeks vs. 3.0% with placebo in adults without diabetes.
- 50.7% of CagriSema users with obesity reached a BMI under 30, compared to 10.2% in the placebo group.
- Ready to turn the market’s comeback into steady cash flow? Grab…

This story appeared on benzinga.com, 2025-06-23 13:10:02.
The Entire Business World on a Single Page. Free to Use →